Checkpoint inhibitors are monoclonal antibodies that target CTLA-4 (ipilimumab), PD-1 (nivolumab, pembrolizumab) or PD-L1 (atezolizumab, durvalumab), on T-cells or cancer cells. This evidence concerns the gene CD274 and cancer.